Fully updated and expanded, in full color with intuitive icons throughout, packed with new and expanded comparison charts, and now with patient handouts as printable PDFs - the classic reference to psychotropic medications is now more "user-friendly" than ever! The Clinical Handbook of Psychotropic Drugs has become a standard reference and practical tool for psychiatrists, psychiatric nurses, pharmacists, psychologists, physicians, and all mental health professionals. The new and fully updated 19th edition retains all the practical features for which the Clinical Handbook is renowned: - Independent, unbiased - Packed with unique comparison charts (dosages, side effects, pharmacokinetics, interactions - ) that allow you to see at a glance which medication is the most suitable for each patient - Instantly recognizable icons and full color throughout, allowing you to find at a glance all the information you seek - The latest information on newly released drugs, adverse effects, approved indications (see below for details) - Succinct, bulleted information on all classes of medication: on- and off-label indications, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more - all you need to know for each class of drug - Patient Handouts, Herbal and "Natural" Products, Unapproved Treatments, ECT, BLT, rTMS New in this edition: - Pharmacotherapy for nicotine/tobacco use - Extensive revisions and additions to the antipsychotics, including dosing, adverse effects, interactions, precautions - New dosage/pharmacokinetics comparison chart for extrapyramidal agents - Extensive revisions to benzodiazepines and hypnotics/sedatives comparison chart - Updates on unapproved treatments (e.g. , pregabalin and vigabatrin for alcohol and cocaine dependence) and herbal and "natural" products (e.g., for treatment of depression) - Hundreds of new references - Printable (PDF) patient handouts - Drugs with recent/changed approval include: lurasidone (Latuda), vilazodone (Viibryd), iloperidone (Fanapt), asenapine sublingual (Saphris), guanfacine (Tenex, Intuniv), degarelix (Firmagon), finasteride (Proscar) - Preparations added include: Symbyax, Prozac Weekly, Luvox CR, Aplenzin, Oleptro, Silenor, Zonolon, Invega Sustenna, Zyprexa Relprevv, Mellaril, Compoz, Epitol, Teril, Nytol, Simply Sleep, Sominex, Unisom, clonidine SR (Kapvay)

Table of Contents:
Antidepressants 2 Selective Serotonin Reuptake Inhibitors (SSRI) 3 Norepinephrine Dopamine Reuptake Inhibitor (NDRI) 15 Serotonin Norepinephrine Reuptake Inhibitor (SNRI) 20 Serotonin-2 Antagonists/Reuptake Inhibitors (SARI) 25 Noradrenergic/Specific Serotonergic Antidepressants (NaSSA) 31 Vilazodone 35 Nonselective Cyclic Antidepressants 37 Monoamine Oxidase Inhibitors 45 Reversible Inhibitor of MAO-A (RIMA) 45 Irreversible Monoamine Oxidase Inhibitors 48 Monoamine Oxidase B Inhibitor 54 Effects of Antidepressants on Neurotransmitters/ Receptors 57 Pharmacological Effects of Antidepressants on Neurotransmitters/Receptors 58 Frequency of Adverse Reactions to Antidepressants at Therapeutic Doses 59 Antidepressant Doses and Pharmacokinetics 62 Switching Antidepressants 65 Antidepressant Augmentation Strategies 67 Electroconvulsive Therapy (ECT) 72 Bright Light Therapy (BLT) 78 Repetitive Transcranial Magnetic Stimulation (rTMS) 80 Antipsychotics 84 "Second-Generation" Antipsychotics/SGAs 90 "Third-Generation" Antipsychotic/TGA 119 "First-Generation" Antipsychotics/FGAs 126 Effects of Antipsychotics on Neurotransmitters/ Receptors 144 Pharmacological Effects of Antipsychotics on Neurotransmitters/Receptors 145 Frequency (%) of Adverse Reactions to Antipsychotics at Therapeutic Doses 146 Antipsychotic Doses and Pharmacokinetics (Oral and Short-Acting Injections) 148 Comparison of Long-Acting IM Antipsychotics 158 Extrapyramidal Adverse Effects of Antipsychotics 162 Switching Antipsychotics 165 Antipsychotic Augmentation Strategies 167 Agents for Treating Extrapyramidal Side Effects 174 Effects on Extrapyramidal Symptoms 178 Comparison of Agents for Treating Extrapyramidal Side Effects 179 Doses and Pharmacokinetics of Agents for Treating Extrapyramidal Side Effects 181 Anxiolytic (Antianxiety) Agents 184 Benzodiazepines 184 Comparison of the Benzodiazepines 192 Buspirone 196 Hypnotics/Sedatives 201 L-Tryptophan 206 Comparison of Hypnotics/Sedatives 209 Mood Stabilizers 214 Lithium 214 Anticonvulsants 222 Comparison of Anticonvulsants 236 Frequency of Adverse Reactions to Mood Stabilizers at Therapeutic Doses 242 Drugs for ADHD 244 Psychostimulants 244 Atomoxetine 252 Comparison of Drugs for ADHD 255 a2 agonists 259 Augmentation Strategies in ADHD 262 Drugs for Treatment of Dementia 264 Cholinesterase Inhibitors 264 Memantine 269 Comparison of Drugs for Treatment of Dementia 271 Sex-Drive Depressants 276 Comparison of Sex-Drive Depressants 278 Drugs of Abuse 280 Alcohol 282 Stimulants 287 Hallucinogens 291 Opiates/Narcotics 298 Inhalants/Aerosols 301 Gamma-hydroxybutyrate (GHB)/Sodium Oxybate 303 Flunitrazepam (Rohypnol) 305 Nicotine/Tobacco 306 Treatment of Substance Use Disorders 309 Disulfiram 309 Acamprosate 312 Naltrexone 314 Methadone 317 Buprenorphine 321 Pharmacotherapy for Nicotine/Tobacco Use Dependence 324 Unapproved Treatments of Psychiatric Disorders 330 Adrenergic Agents 330 Dopaminergic Agents 332 GABA-Agents/Anticonvulsants 334 Hormones 336 Miscellaneous 337 Herbal and "Natural" Products 339 Glossary 347 Suggested Resources for Information Regarding Drug Use in Pregnancy and Effects on Breast Milk 351 Patient Information Sheets 352 Index of Drugs 353